{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T04:54:42Z","timestamp":1697345682501},"reference-count":27,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2004,8,9]],"date-time":"2004-08-09T00:00:00Z","timestamp":1092009600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Liver International"],"published-print":{"date-parts":[[2004,10]]},"abstract":"<jats:p><jats:bold>Abstract: Background\/Aims: <\/jats:bold> We assessed the usefulness of the Cornell Medical Index (CMI) and electroencephalogram (EEG) in the prediction and early detection of psychoneurological symptoms associated with interferon (IFN) therapy for chronic viral hepatitis.<\/jats:p><jats:p><jats:bold><jats:italic>Methods<\/jats:italic>: <\/jats:bold> Forty\u2010eight consecutive patients received IFN for chronic viral hepatitis for 8\u201324 weeks. CMI was measured before IFN therapy. Serial EEGs were recorded before IFN therapy, 2, 4 weeks, and thereafter every 4 weeks in the therapy.<\/jats:p><jats:p><jats:bold><jats:italic>Results<\/jats:italic>: <\/jats:bold> Psychoneurological symptoms including insomnia, depression, and restlessness were seen in 11 (23%) of 48 patients. Five (13%) of 40 patients with CMI I and II and six (75%) of eight with CMI III developed psychoneurological symptoms (<jats:italic>P<\/jats:italic>&lt;0.001). Sensitivity, specificity, and predictive accuracy of CMI III were 55%, 95%, and 75%, respectively. Abnormal EEG such as slow basic rhythm, appeared in 13 patients (27%) during IFN therapy. Psychoneurological symptoms were seen in six (46%) of the 13 patients with abnormal EEG, and in five (14%) of 35 in whom EEG remained normal (<jats:italic>P<\/jats:italic>&lt;0.05).<\/jats:p><jats:p><jats:bold><jats:italic>Conclusions<\/jats:italic>: <\/jats:bold> CMI is useful for the prediction of IFN\u2010induced psychoneurological symptoms in patients with chronic viral hepatitis. Serial EEGs contribute to the screening and auxiliarily assessing the adverse effects of IFN on the central nervous system.<\/jats:p>","DOI":"10.1111\/j.1478-3231.2004.0942.x","type":"journal-article","created":{"date-parts":[[2004,10,12]],"date-time":"2004-10-12T10:42:35Z","timestamp":1097577755000},"page":"407-412","source":"Crossref","is-referenced-by-count":5,"title":["Psychoneurological symptoms during interferon therapy in patients with chronic hepatitis: prospective study on predictive use of Cornell Medical Index and electroencephalogram"],"prefix":"10.1111","volume":"24","author":[{"given":"Yuji","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahito","family":"Nagaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiichi","family":"Tomita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiko","family":"Murase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masamichi","family":"Enya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yohichi","family":"Nishigaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun'ichi","family":"Sugihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisataka","family":"Moriwaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2004,10,12]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840130606"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.286.6361.262"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1983.63"},{"key":"e_1_2_5_5_2","first-page":"958","article-title":"Neurotoxity of interferon","volume":"67","author":"Mattson K","year":"1983","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_5_6_2","first-page":"847","article-title":"Electroencephalographic abnormalities in interferon encephalopathy","volume":"59","author":"Suter C C","year":"1984","journal-title":"a preliminary report"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1159\/000062997"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.1999.tb00720.x"},{"key":"e_1_2_5_9_2","first-page":"530","article-title":"The Cornell Medical Index","volume":"140","author":"Brodman K","year":"1948","journal-title":"an adjust to medical interview"},{"key":"e_1_2_5_10_2","volume-title":"Cornell Medical Index","author":"Kanehisa T","year":"2001"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0327(02)00264-1"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-200X.1992.tb00963.x"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.2302\/kjm.41.25"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.2466\/PR0.92.1.67-74"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1987.00370090055011"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1018852309885"},{"key":"e_1_2_5_17_2","first-page":"93","article-title":"Interferon alpha\u2010induced depression in chronic hepatitis C patients","volume":"37","author":"Malaguarnera M","year":"1998","journal-title":"comparison between different types of interferon alpha"},{"key":"e_1_2_5_18_2","first-page":"505","article-title":"Depression during interferon therapy for chronic viral hepatitis","volume":"12","author":"Scalori A","year":"2000","journal-title":"early identification of patients at risk by means of a computerized test"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1089\/107999001300177457"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200202000-00014"},{"key":"e_1_2_5_21_2","first-page":"211","article-title":"Practical management of patients treated with alpha interferon","volume":"60","author":"Brenard R.","year":"1997","journal-title":"Acta Gastroenterol Belg"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.41.5.672"},{"key":"e_1_2_5_23_2","first-page":"760","article-title":"Fluoxetine treatment of depression caused by interferon \u2010\u03b1","volume":"88","author":"Levenson J L","year":"1993","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-1781(01)00315-8"},{"key":"e_1_2_5_25_2","first-page":"643","article-title":"Neurobehavioral effects of interferon\u2010alpha in cancer patients","volume":"26","author":"Capuron L","year":"2002","journal-title":"phenomenology and paroxetine responsiveness of symptom dimensions"},{"key":"e_1_2_5_26_2","first-page":"368","article-title":"Central nervous system and peripheral immune functions and the sleep\u2013wake system","volume":"19","author":"Moldofsky H.","year":"1994","journal-title":"J Psychiatr Neurosci"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.13-08-03574.1993"},{"key":"e_1_2_5_28_2","first-page":"472","article-title":"Human leukocyte interferon (HuIFN\u2010alpha)","volume":"101","author":"Blalock J E","year":"1981","journal-title":"potent endorphin-like opioid activity"}],"container-title":["Liver International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1478-3231.2004.0942.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1478-3231.2004.0942.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T15:38:14Z","timestamp":1697297894000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1478-3231.2004.0942.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,10]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2004,10]]}},"alternative-id":["10.1111\/j.1478-3231.2004.0942.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1478-3231.2004.0942.x","archive":["Portico"],"relation":{},"ISSN":["1478-3223","1478-3231"],"issn-type":[{"value":"1478-3223","type":"print"},{"value":"1478-3231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,10]]}}}